Charles River Labs Intl Stock
Charles River Labs Intl Stock
Charles River Labs Intl gained 1.540% today.
Charles River Labs Intl is currently one of the favorites of our community with 9 Buy predictions and no Sell predictions.
With a target price of 247 € there is a slightly positive potential of 13.88% for Charles River Labs Intl compared to the current price of 216.9 €.
Pros and Cons of Charles River Labs Intl in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Charles River Labs Intl vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Charles River Labs Intl | 1.540% | 2.167% | -9.436% | 26.288% | 1.831% | -21.413% | - |
| Ironwood Pharmaceuticals | 6.210% | 4.054% | 1.987% | -18.085% | -24.510% | -15.847% | - |
| Sage Therapeutics Inc. | -3.520% | 1.448% | -19.076% | -68.390% | -35.200% | -80.196% | - |
| Novocure Ltd | 2.120% | 16.088% | 3.044% | -77.020% | -3.958% | -91.837% | - |
Comments
Charles River Laboratories International, Inc. (NYSE: CRL) had its price target raised by analysts at Evercore ISI from $260.00 to $265.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International, Inc. (NYSE: CRL) had its price target raised by analysts at UBS Group AG from $270.00 to $290.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International, Inc. (NYSE: CRL) had its price target raised by analysts at Robert W. Baird from $252.00 to $268.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for CRL provided by MarketBeat
News
Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its reference materials for adeno associated virus (AAV) and lentiviral vector (LVV) portfolio, designed to
Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
Charles River Laboratories International, Inc. (NYSE: CRL) today announced it has reached 100 percent renewable electricity across all of its global sites as of the first quarter of 2024
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it is launching its Alternative Methods Advancement Project (AMAP), an initiative dedicated to developing